CHAPTER IVFINAL PROVISIONS
Article 26Transitional provision
The Member States may continue to apply national transposition measures adopted under Commission Directive 2003/94/EC5 to the manufacture of investigational medicinal products used in clinical trials governed by Directive 2001/20/EC of the European Parliament and of the Council6 in accordance with the transitional provisions laid down in Article 98 of Regulation (EU) No 536/2014.
Article 27Entry into force
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
It shall apply from six months after the date of publication in the Official Journal of the European Union of the notice referred to in Article 82(3) of Regulation (EU) No 536/2014 or 1 April 2018, whichever is the later.